Crescita Therapeutics (TSX:CTX) Interest Expense: C$-0.06 Mil (TTM As of Mar. 2026)


TSX:CTX Crescita Therapeutics Inc TSX:CTX
20 GF Score
Price C$0.79
GF Value C$0.68
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Crescita Therapeutics Interest Expense?

Crescita Therapeutics TSX:CTX 20 Interest Expense is C$-0.06 Mil as of Mar. 2026. GuruFocus rates TSX:CTX with a GF Score™ of 20/100 and a GF Value™ of C$0.68 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Crescita Therapeutics's interest expense for the three months ended in Mar. 2026 was C$ -0.03 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.06 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Crescita Therapeutics's Operating Income for the three months ended in Mar. 2026 was C$ -1.21 Mil. Crescita Therapeutics's Interest Expense for the three months ended in Mar. 2026 was C$ -0.03 Mil. Crescita Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Crescita Therapeutics  (TSX:CTX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Crescita Therapeutics's Interest Expense for the three months ended in Mar. 2026 was C$-0.03 Mil. Its Operating Income for the three months ended in Mar. 2026 was C$-1.21 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was C$2.09 Mil.

Crescita Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Crescita Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Crescita Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Crescita Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescita Therapeutics Interest Expense Chart

Crescita Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.24 -0.16 -0.09 -0.07 -0.04

Crescita Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.03
TSX:CTX
20GF Score
Crescita Therapeutics Inc TSX:CTX
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescita Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of C$-0.06 Mil mean?
Crescita Therapeutics (TSX:CTX) has a Interest Expense of C$-0.06 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Crescita Therapeutics and its competitors.
Is Crescita Therapeutics' Interest Expense too high?
Crescita Therapeutics' current Interest Expense is C$-0.06 Mil. Overall, Crescita Therapeutics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Interest Expense compare to ZTS?
Crescita Therapeutics' Interest Expense of C$-0.06 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current Interest Expense is C$-0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (TSX:CTX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.68, compared to a current price of C$0.79 — trading 16.2% above its estimated fair value. The current Interest Expense is C$-0.06 Mil. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current Interest Expense is C$-0.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Crescita Therapeutics (TSX:CTX) Overvalued in 2026?

Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued. The current stock price of C$0.79 is trading 16.2% above its estimated GF Value™ of C$0.68. GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.

Key valuation signals for TSX:CTX:

  • Interest Expense: C$-0.06 Mil
  • GF Value™: C$0.68 vs. price of C$0.79 (16.2% above fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the TSX:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crescita Therapeutics Business Description

Address 2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score

Get the complete analysis for TSX:CTX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.79
Price
C$0.68
GF Value